Trevena Stock Forecast, Price & News

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

What stocks does MarketBeat like better than Trevena?

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevena?

Trevena saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 14,830,000 shares, a decline of 16.0% from the July 29th total of 17,650,000 shares. Based on an average trading volume of 2,250,000 shares, the days-to-cover ratio is currently 6.6 days. Currently, 9.3% of the company's stock are short sold.
View Trevena's Short Interest.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Trevena.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Thursday, August, 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. Trevena had a negative trailing twelve-month return on equity of 40.89% and a negative net margin of 1,194.62%.
View Trevena's earnings history.

How has Trevena's stock been impacted by COVID-19 (Coronavirus)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TRVN stock has increased by 86.1% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRVN?

2 brokerages have issued 12-month price targets for Trevena's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's stock price to reach $6.00 in the next year. This suggests a possible upside of 361.5% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:

• Carrie L. Bourdow, President, Chief Executive Officer & Director
• Barry Shin, Chief Financial Officer & Senior Vice President
• Mark A. Demitrack, Chief Medical Officer & Senior Vice President
• Angela Bagley, Vice President-Technical Operations
• Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

Who are some of Trevena's key competitors?

Some companies that are related to Trevena include Immuneering (IMRX), Dyne Therapeutics (DYN), Akero Therapeutics (AKRO), ADVANZ PHARMA (CXRXF), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Crinetics Pharmaceuticals (CRNX), Cara Therapeutics (CARA), Endo International (ENDP), Oramed Pharmaceuticals (ORMP), Lexicon Pharmaceuticals (LXRX), Amryt Pharma (AMYT), Shattuck Labs (STTK), Veru (VERU) and OrganiGram (OGI).
View all of TRVN's competitors.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.79%), Vanguard Group Inc. (4.68%), Geode Capital Management LLC (1.65%), State Street Corp (1.62%), Northern Trust Corp (0.35%) and Nuveen Asset Management LLC (0.34%).
View institutional ownership trends for Trevena.

Which major investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cubist Systematic Strategies LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., Group One Trading L.P., Jacobi Capital Management LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

Which major investors are buying Trevena stock?

TRVN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Northern Trust Corp.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.30.

How much money does Trevena make?

Trevena has a market capitalization of $213.86 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29,370,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].